Filing search / Legend Biotech Corporation / "Healthcare"

6-K

EX-99.1

LEGN Legend Biotech Corporation

27 Sep 24

Current report (foreign)

4:35pm

for 10 days following CARVYKTI® infusion at a REMS-certified healthcare facility for signs and symptoms of CRS. Monitor patients for signs or symptoms … Reactions (6.1)]. Monitor patients at least daily for 10 days following CARVYKTI® infusion at the REMS-certified healthcare facility for signs

6-K

EX-99.1

LEGN Legend Biotech Corporation

9 Aug 24

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

7:01am

quarter, approval of CARVYKTI® in the second line increased demand and interest from patients and the healthcare community. Momentum for CARVYTKI® … The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) approved CARVYKTI® for the treatment of adult patients with relapsed

6-K

LEGN Legend Biotech Corporation

8 Aug 24

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

4:05pm

in multiple Yale healthcare programs, including the Yale Center for Emotional Intelligence, which he founded; the Center for Interdisciplinary Research

6-K

EX-99.1

LEGN Legend Biotech Corporation

8 Aug 24

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

4:05pm

. Salovey also played key roles in multiple Yale healthcare programs, including the Yale Center for Emotional Intelligence, which he founded; the Center

6-K

EX-99.1

LEGN Legend Biotech Corporation

2 Jul 24

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

8:00am

of corticosteroids for treatment of CRS. Monitor patients at least daily for 10 days following CARVYKTI® infusion at a REMS-certified healthcare facility for signs … at the REMS-certified healthcare facility for signs and symptoms of ICANS. Rule out other causes of ICANS symptoms. Monitor patients for signs

6-K

EX-99.1

f7bddrndr

3 Jun 24

Current report (foreign)

4:05pm

6-K

EX-99.1

u5125y3f

23 May 24

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

5:00pm

6-K

EX-99.1

wkeu7g9jypr m4rmjeo

22 Apr 24

Current report (foreign)

1:06pm

6-K

EX-99.1

f01sgh vu13znt

8 Apr 24

Current report (foreign)

7:03am

6-K

EX-99.1

97ag wkh767jp18wdgz

15 Mar 24

FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study

3:18pm

6-K

EX-99.1

pfnhv

23 Feb 24

Current report (foreign)

7:16am

6-K

ka13j mbt6y1yu

9 Jan 24

Legend Biotech Corporation 6-K

4:01pm

6-K

EX-99.1

1xiaqgmt

11 Dec 23

Legend Biotech Corporation 6-K

7:32pm

6-K

recig gtdgnye2c4

20 Nov 23

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

6:02am

6-K

EX-99.1

bhz7uz4cvhc0021nbu

20 Nov 23

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

6:02am

6-K

EX-99.1

hdxcj1l czqmu90

6 Jun 23

Legend Biotech Corporation 6-K

4:44pm

6-K

EX-99.1

wuh0ni5x 9ogb709v

5 Jun 23

Legend Biotech 6-K

11:17am